537 related articles for article (PubMed ID: 38022642)
1. SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.
Pandey R; Bakay M; Hakonarson H
Front Immunol; 2023; 14():1271102. PubMed ID: 38022642
[TBL] [Abstract][Full Text] [Related]
2. SOCS modulates JAK-STAT pathway as a novel target to mediate the occurrence of neuroinflammation: Molecular details and treatment options.
Yan M; Sun Z; Zhang S; Yang G; Jiang X; Wang G; Li R; Wang Q; Tian X
Brain Res Bull; 2024 May; 213():110988. PubMed ID: 38805766
[TBL] [Abstract][Full Text] [Related]
3. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
5. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
6. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
7. JAK-STAT signaling pathway in non-infectious uveitis.
Su Y; Tao T; Liu X; Su W
Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
9. Potential Natural Biomolecules Targeting JAK/STAT/SOCS Signaling in the Management of Atopic Dermatitis.
Kopalli SR; Annamneedi VP; Koppula S
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889539
[TBL] [Abstract][Full Text] [Related]
10. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
11. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
[TBL] [Abstract][Full Text] [Related]
12. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway.
Cooney RN
Shock; 2002 Feb; 17(2):83-90. PubMed ID: 11837794
[TBL] [Abstract][Full Text] [Related]
13. A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis.
Ahmed CM; Massengill MT; Brown EE; Ildefonso CJ; Johnson HM; Lewin AS
Exp Eye Res; 2018 Dec; 177():12-22. PubMed ID: 30048621
[TBL] [Abstract][Full Text] [Related]
14. SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications.
Liang Y; Xu WD; Peng H; Pan HF; Ye DQ
Eur J Immunol; 2014 May; 44(5):1265-75. PubMed ID: 24595859
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
16. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.
Wen J; Hu H; Chen M; Yang H; Zhao Y; Liu Y
J Immunol Res; 2021; 2021():2324400. PubMed ID: 34966823
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
18. [JAK inhibitors: Perspectives in internal medicine].
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Rev Med Interne; 2019 Dec; 40(12):816-825. PubMed ID: 31699450
[TBL] [Abstract][Full Text] [Related]
19. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
